Cosima Brucker
YOU?
Author Swipe
View article: Stress and psychological trauma as predictors of cancer-related fatigue in breast cancer patients (SaFE study)—study protocol of a prospective follow-up study
Stress and psychological trauma as predictors of cancer-related fatigue in breast cancer patients (SaFE study)—study protocol of a prospective follow-up study Open
Introduction Cancer-related fatigue (CRF) is a common symptom of cancer and/or its treatment. Most cancer patients are affected during treatment, as well as years thereafter. Around a third of survivors report suffering from CRF. Those aff…
View article: Somatic cells compartmentalise their metabolism to sustain germ cell survival
Somatic cells compartmentalise their metabolism to sustain germ cell survival Open
To ensure success in reproduction, organisms dedicate substantial resources to supporting the germline. In testes, somatic gonadal cells form a barrier that isolates germ cells from circulating nutrients, raising the question of how germ c…
View article: Relationships Between H2S and OT/OTR Systems in Preeclampsia
Relationships Between H2S and OT/OTR Systems in Preeclampsia Open
Pre-eclampsia (PE) is a hypertensive pregnancy complication. Oxidative stress is hypothesized to contribute to the pathophysiology of PE. Both the hydrogen sulfide (H2S) and oxytocin (OT) systems might play a role in the pathophysiology of…
View article: Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, <scp>HER2</scp>‐negative early breast cancer treated with upfront letrozole: Experiences from the phase <scp>IV PreFace</scp> trial
Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, <span>HER2</span>‐negative early breast cancer treated with upfront letrozole: Experiences from the phase <span>IV PreFace</span> trial Open
Patients with hormone receptor‐positive (HRpos), HER2‐negative (HER2neg) breast cancer (BC) benefit less from neoadjuvant chemotherapy (NACT) than patients with triple‐negative and HER2‐positive BC. In this retrospective analysis of the ph…
View article: The role of the H<sub>2</sub>S and OT systems in pre-eclampsia
The role of the H<sub>2</sub>S and OT systems in pre-eclampsia Open
Pre-eclampsia (PE) is a hypertensive pregnancy complication. Oxidative stress is hypothesized to contribute to the pathophysiology of PE. Both the hydrogen sulfide (H 2 S) and oxytocin (OT) systems might play a role in the pathophysiology …
View article: Impact of Mass Drug Administration with Ivermectin, Diethylcarbamazine, and Albendazole in Elimination of Lymphatic Filariasis in Five Districts of Nepal
Impact of Mass Drug Administration with Ivermectin, Diethylcarbamazine, and Albendazole in Elimination of Lymphatic Filariasis in Five Districts of Nepal Open
Background Nepal aims to eliminate Lymphatic Filariasis (LF) by 2030. Mass drug administration (MDA) has ceased in 53 of 64 endemic districts. In 2023, five districts with persistent LF (≥2% antigen prevalence) completed two rounds of MDA …
View article: Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study Open
View article: Eosinophilic esophagitis patients report substantial disease burden comparable to more systemic immune-mediated diseases
Eosinophilic esophagitis patients report substantial disease burden comparable to more systemic immune-mediated diseases Open
EoE patients' perceived impairment in everyday life, particularly within subdomains such as leisure, is substantial and comparable to that experienced by patients with other immune-mediated disease states, including IBD. Notably, patient-p…
View article: 338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial
338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial Open
View article: Psychological, neuroendocrine and inflammatory stress responses in women after miscarriage or stillbirth: investigating early psychobiological adaptations to potential traumatic events
Psychological, neuroendocrine and inflammatory stress responses in women after miscarriage or stillbirth: investigating early psychobiological adaptations to potential traumatic events Open
View article: Association between concerns regarding COVID-19 mRNA vaccination and the adverse event rate among healthcare workers
Association between concerns regarding COVID-19 mRNA vaccination and the adverse event rate among healthcare workers Open
Healthcare workers must be vaccinated regularly. However, vaccination-related side effects can lead to sick leaves and decreased willingness to be vaccinated. Negative expectations can cause nocebo effects, potentially increasing the rates…
View article: Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial Open
Introduction: The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In a…
View article: Structural Requirements for the Outpatient Treatment of Benign Diseases of the Uterus
Structural Requirements for the Outpatient Treatment of Benign Diseases of the Uterus Open
In many cases, outpatient surgical treatment of benign diseases of the uterus has advantages over inpatient care. This has been demonstrated by the healthcare situation in other countries. However, the prerequisite for the provision of out…
View article: Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole Open
Patient populations eligible for monarchE and NATALEE trials differed. Nearly a third of the postmenopausal HRpos population, previously under upfront letrozole treatment, met the NATALEE prognostic eligibility criteria. As certain eligibl…
View article: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study Open
Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Ne…
View article: 216P What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine? Real-world data from the RIBANNA study (6th interim analysis (IA))
216P What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine? Real-world data from the RIBANNA study (6th interim analysis (IA)) Open
RIBANNA is a German prospective, non-interventional study assessing the efficacy and safety of RIB + AI/FUL, endocrine therapy (ET) or chemotherapy (CT) in 1st line (1L) and subsequent therapy lines in pre-, peri-and postmenopausal women w…
View article: Immunometric and functional measurement of endogenous vasoinhibin in human sera
Immunometric and functional measurement of endogenous vasoinhibin in human sera Open
Introduction Circulating levels of the antiangiogenic protein vasoinhibin, a fragment of prolactin, are of interest in vasoproliferative retinopathies, preeclampsia, and peripartum cardiomyopathy; however, it is difficult to determine the …
View article: Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4, and -5 in Ovarian Adenocarcinomas
Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4, and -5 in Ovarian Adenocarcinomas Open
Background: Histone deacetylases (HDACs) are implicated in carcinogenesis, and HDAC inhibitors (HDACis) are explored as a therapeutic tool in several tumors. The aim of this study was to evaluate the clinical significance of HDAC-2, -4, an…
View article: Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4 and -5 in Ovarian Adenocarcinomas
Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4 and -5 in Ovarian Adenocarcinomas Open
Background: Histone deacetylases (HDACs) are implicated in carcinogenesis, and HDAC inhibitors (HDACis) are explored as a therapeutic tool in several tumors. The aim of this study was to evaluate the clinical significance of HDAC -2, -4, a…
View article: Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study Open
[This corrects the article DOI: 10.1055/a-2238-3153.].
View article: Total Pelvic Floor Lifting: A New Approach for the Anatomic Repair of Pelvic Floor Hypermobility and Vaginal Laxity in Parous Women
Total Pelvic Floor Lifting: A New Approach for the Anatomic Repair of Pelvic Floor Hypermobility and Vaginal Laxity in Parous Women Open
Summary: Recent years have seen a steady increase in the information available regarding pelvic floor changes after childbirth. Obstetric trauma, to which all structures of the urogenital sphere are subjected, can affect different anatomic…
View article: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study Open
Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Ne…
View article: SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer
SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer Open
View article: Prognostic Impact of Selection Criteria of Current Adjuvant Endocrine Therapy Trials Natalee and Monarche in Postmenopausal Hrpos/Her2neg Breast Cancer Patients Treated with Upfront Letrozole
Prognostic Impact of Selection Criteria of Current Adjuvant Endocrine Therapy Trials Natalee and Monarche in Postmenopausal Hrpos/Her2neg Breast Cancer Patients Treated with Upfront Letrozole Open
View article: Correction: Apical prolapse correction by unilateral pectineal suspension
Correction: Apical prolapse correction by unilateral pectineal suspension Open
View article: 441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study
441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study Open
View article: 409P Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
409P Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)) Open
View article: #384 First interim analysis of the SCOUT-1 Study (NOGGO Ov54, NCT04830709): a non-interventional study to evaluate treatment patterns and longterm outcome in patients with newly diagnosed advances ovarian cancer
#384 First interim analysis of the SCOUT-1 Study (NOGGO Ov54, NCT04830709): a non-interventional study to evaluate treatment patterns and longterm outcome in patients with newly diagnosed advances ovarian cancer Open
Introduction/Background The current standard of care for advanced ovarian cancer (OC) consists of upfront surgery, with the goal of complete macroscopic resection, followed by platinum-based chemotherapy and maintenance therapy (MTX) with …
View article: Apical prolapse correction by unilateral pectineal suspension
Apical prolapse correction by unilateral pectineal suspension Open
View article: SUCCOR Nodes: May Sentinel Node Biopsy Determine the Need for Adjuvant Treatment?
SUCCOR Nodes: May Sentinel Node Biopsy Determine the Need for Adjuvant Treatment? Open